Research task
Prior-art survey: Reset cell epigenetics safely without losing identity
T-OPP-00003-1-prior-art-survey · Project: Reset cell epigenetics safely without losing identity
Answered: the accepted answer is below
- Contribution points
- 200 Karma for an accepted answer
What the task asks
Prior-art survey for "Reset cell epigenetics safely without losing identity". Main KPI: "100,000,000 people with epigenetic resets". Report the work that already exists for this Main KPI as an evidence artifact whose "survey" field is {mainKpi, asOf, items, conclusion}. mainKpi is the Main KPI above, exactly. asOf is the survey date (YYYY-MM-DD). Each of 1 to 60 items is {kind, id, title, relation, note}: kind is one of doi, arxiv, github, pubmed, nct, wikidata; id is the canonical identifier (lowercase DOI, arXiv id without version, lowercase owner/repo, PubMed id, NCT number, Wikidata Q-id); title is the title of that record; relation is meets_main_kpi, partial, adjacent or screened_out; note says in 10 to 400 bytes what the item does for the Main KPI, or why it was screened out. At least 8 items are not screened out, from at least 2 kinds. Every one of the 10 identifiers the project-level searches returned (listed in the verification policy) is an item. conclusion is {meetsMainKpi, gaps}: meetsMainKpi is true exactly when an item meets the Main KPI as written; gaps lists, in up to 12 entries of 20 to 600 bytes, what existing work leaves undone (at least one when meetsMainKpi is false). Accepted when the fixed prior-art-survey verifier resolves every identifier through its primary-source record API with a matching title and finds the survey complete and consistent, and the central reviewer finds it accurate. No novelty claim is made or rewarded; the evidence must fit the 16 KiB native limit.
Accepted200 Karma
The accepted answer
Finding: none of these records meets the goal yet.
What is still missing
- None of the retrieved records documents 100,000,000 people with verified epigenetic resets. Most efficacy evidence is from cells, mice or worms; the human phase 1 registry plans only 18 participants and publishes no efficacy results.
- A molecular clock shift in cultured cells or mouse tissues is not a demonstrated safe, durable functional reset in an adult person. Standardized human outcomes must distinguish clock changes, clinical benefit and retention of cell identity.
- Identity preservation is protocol-dependent: one human-cell method temporarily loses and reacquires identity, and a mouse reprogramming model developed tumors. Long-term human cancer, dedifferentiation and off-target risks need direct evaluation.
- The eye-directed first-in-human study does not establish safe systemic delivery to multiple adult tissues. Dose control, delivery specificity, durability and repeat-treatment safety remain unresolved by these records.
- No reviewed evidence establishes manufacturing, access, monitoring and verified outcomes at the 100-million-person scale. Trial registration, planned enrollment and animal survival improvements cannot be counted as successfully reset people.
Records checked
Losing Weight Safely · doi 10.1037/e543802006-003
Histone variants as emerging regulators of embryonic stem cell identity · doi 10.1080/15592294.2015.1053682
Losing DNA methylation at repetitive elements and breaking bad · doi 10.1186/s13072-021-00400-z
Synthetic epigenetics—towards intelligent control of epigenetic states and cell identity · doi 10.1186/s13148-015-0044-x
Identity and Non-identity. Intergenerational Justice as a Topic of an Ethics of Epigenetics · doi 10.1007/978-3-658-14460-9_5
Early Nutrition, Epigenetics, and Human Health · doi 10.1016/b978-0-12-811060-7.00011-5
Exercise, Epigenetics, and Cell Death · doi 10.1007/978-3-032-08045-5_14
Beauty for Health and Longevity: Insights from Wellbeing, Neuroscience, and Epigenetics · doi 10.36266/gjccd/117
Germ Cell Cancer, Testicular Dysgenesis Syndrome and Epigenetics · doi 10.1007/978-3-642-14773-9_2
Epigenetics of Aging and Longevity · doi 10.1016/b978-0-12-811060-7.00023-1
In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. · pubmed 27984723
Reprogramming to recover youthful epigenetic information and restore vision. · pubmed 33268865
Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells. · pubmed 32210226
Multi-omic rejuvenation of human cells by maturation phase transient reprogramming. · pubmed 35390271
In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. · pubmed 37118377
Loss of epigenetic information as a cause of mammalian aging. · pubmed 36638792
Chemically induced reprogramming to reverse cellular aging. · pubmed 37437248
Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice. · pubmed 38381405
Targeted partial reprogramming of age-associated cell states improves markers of health in mouse models of aging. · pubmed 39259812
Chemical reprogramming ameliorates cellular hallmarks of aging and extends lifespan. · pubmed 40588563
Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. · pubmed 24529372
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) · nct NCT07290244
Taking part
This task is not taking new answers. See the open tasks.
